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Abstract
Objective
The aim of this study was to expand the spectrum of epilepsy syndromes related to STX1B, encoding the
presynaptic protein syntaxin-1B, and establish genotype-phenotype correlations by identifying further disease-
related variants.
Methods
We used next-generation sequencing in the framework of research projects and diagnostic testing. Clinical data
and EEGs were reviewed, including already published cases. To estimate the pathogenicity of the variants, we used
established and newly developed in silico prediction tools.
Results
We describe 17 new variants in STX1B, which are distributed across the whole gene. We discerned 4 diﬀerent
phenotypic groups across the newly identiﬁed and previously published patients (49 patients in 23 families): (1) 6
sporadic patients or families (31 aﬀected individuals) with febrile and afebrile seizures with a benign course, generally
good drug response, normal development, and without permanent neurologic deﬁcits; (2) 2 patients with genetic
generalized epilepsy without febrile seizures and cognitive deﬁcits; (3) 13 patients or families with intractable seizures,
developmental regression after seizure onset and additional neuropsychiatric symptoms; (4) 2 patients with focal
epilepsy. More often, we found loss-of-function mutations in benign syndromes, whereas missense variants in the
SNARE motif of syntaxin-1B were associated with more severe phenotypes.
Conclusion
These data expand the genetic and phenotypic spectrumof STX1B-related epilepsies to a diverse range of epilepsies that
span the International League Against Epilepsy classiﬁcation. Variants in STX1B are protean and contribute to many
diﬀerent epilepsy phenotypes, similar to SCN1A, the most important gene associated with fever-associated epilepsies.
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Genetic generalized epilepsies (GGEs) and genetic epilepsies
with febrile seizures (FS) plus (GEFS+) are genetically and
phenotypically heterogeneous epileptic disorders. GGEs share
common clinical hallmarks such as seizure types, generalized
epileptic discharges on EEG, and typical onset between child-
hood and adolescence. Most GGE cases have a polygenic in-
heritance, but a few monogenic causes have been identiﬁed,
such as GABRA1,1 SLC2A1,2 CACNA1H,3 as well as micro-
deletions, such as 15q13.3.4 GEFS+ is a familial epilepsy syn-
drome characterized by focal or generalized febrile and afebrile
seizures, and focal or generalized epileptiform discharges on
EEG. The clinical presentation may diﬀer considerably among
aﬀected individuals within the same family.5,6 Privatemutations
have been identiﬁed in genes encoding subunits of voltage-
gated Na+ channels (SCN1A, SCN1B)7,8 and the γ-amino-
butyric acid type A receptor (GABRG2, GABRD).9,10 Most of
the genes that are associated with GGE and GEFS+ are also
implicated in developmental and epileptic encephalopathies
(DEEs), which are characterized by seizure onset in the ﬁrst
years of life, often pharmacoresistant seizures, cognitive re-
gression, and neurologic deﬁcits. For certain genes, such as
SCN1A, a clear genotype-phenotype correlation is described: in
GEFS+, a greater proportion of missense variants is found,
whereas in Dravet syndrome, nonsense mutations or large
deletions are more common.11
Recently, we reported variants in the STX1B gene as a cause of
fever-associated epilepsies of variable severity.12 Two large
families showed a rather benign course of GEFS+ syndrome,
whereas 4 individuals had a more severe DEE phenotype. An
additional 18-year-old patient exhibiting epilepsy with
myoclonic-atonic seizures and moderate to severe intellectual
disability was reported recently.13
STX1B encodes syntaxin-1B, a presynaptic protein that is part
of the SNARE complex mediating the process of calcium-
dependent synaptic vesicle release.14
We aimed to describe additional variants in STX1B, charac-
terize the related clinical and EEG phenotypic spectrum, and
establish genotype-phenotype correlations.
Methods
Clinical data
We identiﬁed 49 individuals harboring heterozygous variants
in STX1B (NM_052874.3). The cases were pooled from
14 diﬀerent centers identiﬁed through research studies and
clinical diagnostic testing. The cohort consists of 7 families
with 2 to 17 aﬀected individuals and 16 sporadic patients. Of
these, we previously reported 2 large families and 4 sporadic
patients.12,15,16 We systematically collected clinical in-
formation such as age at onset, seizure type, neurologic and
cognitive deﬁcits, neuroimaging outcome, and antiepileptic
drug (AED) treatment through a standardized questionnaire.
We reviewed original EEG recordings (S. Wolking., H.L., T.D.,
C.M., P.W.-W., D.M.) for all but 3 patients (F3, F15, F18).
EEGs for F1 and F2were described in previous publications.15,16
Standard protocol approvals, registrations,
and patient consents
Written informed consent to participate in this study was
obtained from all patients or caregivers.
Genetics
We used diﬀerent next-generation sequencing datasets from
multicenter research projects or diagnostic testing services to
identify the reported STX1B variants. The methods and the
centers are available fromDryad (doi:10.5061/dryad.cf0hj73)
and in our previous report.12 All patients are of European
descent.
To evaluate the eﬀect of the missense variants, we used well-
established in silico prediction tools: SIFT (sorting tolerant
from intolerant),17 PolyPhen-2 (polymorphism phenotyping
v2),18 and MutationTaster.19 We compared patient STX1B
missense variants to variants identiﬁed in almost 150,000
control individuals stored in the Genome Aggregation Data-
base (gnomAD, gnomad.broadinstitute.org/).20 Mutation
density was calculated by counting the number of variant
positions in gnomAD divided by the window length within
a window of 10 nucleotides using a sliding window approach
over the coding sequence of the STX1B transcript NM_
052874.3. We determined paralog conservation as described
by Lal et al.21 In short, we aligned the canonical protein
sequences of the 7 paralog genes of the Ensembl SYNTAXIN
protein family, STX2, STX1A, STX11, STX1B, STX19, STX3,
and STX4 and scored the conservation at each alignment
position using JalView.22 Then we determined the mean and
the standard deviation paralog conservation for each single
protein of the protein family and a z score (para_zscore)
calculated for each residue position. We deﬁned paralog
conservation as para_zscore >0.
Data availability
Data not published in this article will be shared as anonymized
data by request from any qualiﬁed investigator.
Glossary
DEE = developmental and epileptic encephalopathy; FS = febrile seizures;GEFS+ = genetic epilepsies with febrile seizures plus;
GGE = genetic generalized epilepsy; gnomAD = Genome Aggregation Database; GTCS = generalized tonic-clonic seizure;
JME = juvenile myoclonic epilepsy; PolyPhen-2 = polymorphism phenotyping v2; SIFT = sorting tolerant from intolerant;
SNARE = SNAP (soluble NSF attachment protein) receptor.
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Table 1 Condensed phenotypes of patients and families F1–F23
ID No. Variant
FS; AaO
(y)
Nonfebrile
seizures;
AaO (y),
seizure
type
Intellectual
disability
Neurologic
examination EEG
Outcome
(current
AEDs)
Genetic
epilepsy with
febrile seizures
plus
F1 17 c.166C>T; p.Q56* 1.5-7; 3
patients
w/o FS
1.7-6; 2
exceptions
with onset
in
adulthood;
GTCS (6), AS
(4), Abs (4),
TS (2)
Asperger
syndrome (2)
Normal 3-4/s GSW (5),
FSW (1)
All Sf,
most w/o
treatment
F2 8 c.133_
134insGGATGTGCATTG;
p.K45delinsRCMIE and
c.135_136AC>GA;
p.L46M
1.2-3; 2
patients
w/o FS
1.2-1.7;
GTCS (5),
FIAS (3), AS
(3)
Dyslexia (1),
dyscalculia (1),
learning
disability (1)
Macrocephaly
(1)
FSW (7), GSW (7) All Sf, 4
w/o
treatment
F7 1 c.23_26dupTGCG;
p.S10Afs*7; de novo
0.8/NA,
GTCS
1.3; GTCS Normal Mild
hypotonia
NA Os (VPA)
F8 3 c.852dup; p.T285Dfs*75 0.9-1.4 5 (1); GTCS,
TS
Learning
disability (1)
Normal FSW (1) All Sf, 2
under
treatment
(VPA, PB)
F9 1 c.733C>T; p.R245* 2; FIAS,
GTCS
3; FIAS Normal Normal FSW Sf (OXC)
F10 1 c.420C>G; p.Y140* 2; AS,
GTCS
NA Mild Mild
dysmorphic
features
FSW Sf (VPA,
CLB)
Genetic
generalized
epilepsy
F11 1 c.628G>A; p.E210K NA 18; GTCS,
Myo, Abs
Impaired
executive
functions
Normal GSW,
photosensitive
Os (LEV,
CLB)
F12 1 c.277A>T; p.K93* NA 11; GTCS,
Myo
Normal Normal GSW Sf (VPA,
LEV, TPM)
Developmental
and epileptic
encephalopathy
F3 1 c.140C>A; p.S47*, de
novo
uk uk uk uk uk uk
F4 1 c.657T>A; p.V216E NA 3.5; GTCS,
TS, Myo, Abs
Moderate
cognitive
impairment
Ataxia,
dysarthria,
macrocephaly
FSW, GSW Os (VPA,
LTG)
F5 1 c.678G>C, p.G226R, de
novo
1.1 1.7; GTCS,
Myo, Abs,
AS, TS
Developmental
regression
Ataxia 3.5/s GSW, FSW Sf (LEV,
STP, VPA)
F6 1 arr[hg19] 16p11.2
(30,332,532-31,104,012)
x1; de novo
NA 1.1; Myo, AS,
GTCS
Developmental
regression
Mild
dysmorphic
features
FSW Os (CLB,
STP)
F13 2 c.563dupA; p.N189Afs*5 NA 0.8-1.3; Myo
(2), atyp Abs
(2), GTCS (2),
TS (2)
Developmental
regression (1)
Ataxia (1),
dystonia (1)
FSW (2), GSW (2) Os (PHT,
VPA, CBZ,
VGB)
Continued
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Results
Phenotypic descriptions
Reviewing the clinical characteristics of all patients, we could
distinguish 4 diﬀerent phenotypic groups (numbering of the
families was deﬁned as follows: F1–F6 as in our previous
study,12 F7–F23 new families sorted by phenotype). (1)
Three families and 3 sporadic patients with FS, with or
without additional generalized and more rarely focal afebrile
seizures, with a relatively benign course, generally good drug
response, normal development, and mild or no neuropsy-
chiatric symptoms, corresponding to GEFS+ (F1, 2, 7–10).
(2) Two unrelated patients with generalized myoclonic and
absence seizures, without FS, and without major cognitive
deﬁcits, corresponding to juvenile myoclonic epilepsy (JME),
a common subtype of GGE (F11, 12). (3) Thirteen unrelated
patients with intractable seizures, occurrence of de-
velopmental stagnation or regression after seizure onset, and
additional neuropsychiatric deﬁcits compatible with DEE
(F3–6, F13–21). (4) Two patients with some form of focal
epilepsy (F22, 23). The main clinical characteristics of all
families and sporadic patients are summarized in table 1. More
detailed clinical data are available from Dryad, doi.org/10.
5061/dryad.cf0hj73.
Group 1: GEFS+ (31 patients in families F1, F2, F7–10)
FS were present in the majority of patients. The ﬁrst seizure
started between 10 months and 5 years (median 20 months).
There was a large variety of afebrile seizure types, including
generalized tonic-clonic seizures (GTCS) (n = 13), focal
impaired awareness seizures (n = 3), atonic seizures (n = 8),
tonic seizures (n = 4), and absence seizures (n = 5). Nine
patients had infrequent seizures until adulthood that did not
require treatment. For most cases, cognition was intact and
neurologic deﬁcits were not frequent in this cohort (table 1).
Asymptomatic variant carriers were identiﬁed in 2 families (4
Table 1 Condensed phenotypes of patients and families F1–F23 (continued)
ID No. Variant
FS; AaO
(y)
Nonfebrile
seizures;
AaO (y),
seizure
type
Intellectual
disability
Neurologic
examination EEG
Outcome
(current
AEDs)
F14 1 c.845T>C; p.I282T; de
novo
1.3 2; Abs, Myo,
AS, TS
Developmental
regression
Ataxia,
aphasia
GPSW, GSW Os (VPA,
BR, ESM)
F15 1 c.773G>A; p.S258N uk uk uk uk uk uk
F16 1 c.662T>C; p.L221P 2 3; GTCS,
Abs, Myo,
AS, CPS
Developmental
stagnation
Mild ataxia GPSW, GPS Os (VPA,
LTG, LEV,
CLB)
F17 1 c.155delA; p.Q52Rfs*2;
de novo
1.3 4; GTCS,
Myo, Abs, AS
Developmental
regression
Dysarthria,
ataxia
GSW Os (LEV,
VPA)
F18 1 c.431G>T; p.C144F; de
novo
NA 0.8/16; Abs Developmental
stagnation
Ataxia,
tremor,
dysarthria
uk Sf (NA)
F19 1 c.736 G>C; p.A246P; de
novo
NA Since birth;
IS
Severely
impaired
Severe motor
and speech
impairment
Hypsarrhythmia Os (CBD)
F20 2 c.(?_242)_(*3565_?)del 2 (2) 2; AS (1), Abs
(1), Myo (1),
GTCS
Intellectual
impairment
Ataxia GPSW, GSW Os (VPA)
F21 1 c.383del; p.Q128Gfs*2 NA 0.2/Myo,
apnea and
cyanosis
Developmental
stagnation
Hypotonia GPSW Sf (CLB)
Focal epilepsy
F22 1 c.782G>A; p.R261Q 6 6; GTCS,
FIAS
Normal Normal FSW (right
temporal)
Os (OXC,
LCM, ZNS)
F23 1 c.262G>T; p.V88F NA 12; GTCS,
FIAS
Normal Normal FSW (left
temporal)
Sf (LTG)
Abbreviations: AaO = age at onset; Abs = absence seizure; AED = antiepileptic drug; AS = atonic seizure; atyp = atypical; BR = bromide; CBD = cannabidiol;
CBZ = carbamazepine; CLB= clobazam; CPS = complex partial seizure; ESM= ethosuximide; FIAS = focal impaired awareness seizure; FS = febrile seizures; FSW
= focal sharp waves; GPS = generalized polyspikes; GPSW = generalized polyspikes and sharpwaves; GSW = generalized sharp waves; GTCS = generalized
tonic-clonic seizure; IS = infantile spasms; LCM = lacosamide; LEV = levetiracetam; LTG = lamotrigine; Myo = generalized myoclonic seizure; NA = not
applicable; Os = ongoing seizures; OXC = oxcarbazepine; PB = phenobarbitone; PHT = phenytoin; Sf = seizure free; STP = stiripentol; TPM = topiramate; TS =
tonic seizure; uk = unknown; VGB = vigabatrin; VPA = valproic acid; w/o = without; ZNS = zonisamide.
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in F1, 3 in F2), which is of importance for genetic testing and
counseling in mild cases. Moreover, in F1, 4 phenocopies
were identiﬁed (2 patients with a GGE phenotype not
matching GEFS+, 1 individual with a single FS, and 1 patient
with falls and head nodding in early childhood that were later
interpreted as nonepileptic15).The treatment outcome in this
group was overall positive. More than 50% of patients were
seizure-free without medication (17); the remainder were
seizure-free with AED treatment (11). Only patient F7 had
ongoing seizures with valproic acid. EEGs showed focal and
generalized epileptiform discharges. Available ictal recordings
in F8.1 showed focal onset seizure.
Group 2: GGE (2 patients, F11, F12)
The ﬁrst seizures for patient F11 were at age 18 years (gen-
eralized myoclonic seizures) followed by GTCS at 20 years,
and absences at 21 years. GTCS occurred in clusters of 3 or 4
seizures every 3 months. On neuropsychological examination,
the patient showed slight executive dysfunction; however, IQ
and memory functions were normal. F12 had his ﬁrst seizures
at 11 years, featuring both afebrile myoclonic seizures and
GTCS. AWechsler Adult Intelligence test at 19 years revealed
an IQ of 85 ± 3. On examination, neither patient showed
deﬁcits. Treatment was diﬃcult, requiring multiple AED trials
in both patients (table 1).
For F11, the ﬁrst EEG at age 21 showed an unusual pattern of
frequent bursts of generalized slow waves associated with
myoclonic jerks of both shoulders. Later, typical generalized
bursts of spikes and sharp waves were documented under
photic stimulation (he was the only photosensitive patient in
the whole cohort, as far as this was examined). For F12, the
ﬁrst available EEG was performed at age 19 and showed oc-
casional brief bilateral epileptic discharges. A video-EEG at
age 24 demonstrated 4-Hz generalized spike-wave activity.
Video-EEGmonitoring at age 31 showed no epileptic activity.
Group 3: DEE (15 patients, F3–6, F13–21)
We retrieved detailed phenotypes for 12 of 15 patients. Epi-
lepsy onset was between 0 months and 3.5 years (median 15
months). Six patients (F5, F14, F16, F17, F20) had FS with
onset between 13 months and 2 years. F14 had only a single
FS after vaccination. Afebrile seizures comprised GTCS (n =
9), myoclonic (n = 10), atonic (n = 8), tonic seizures (n = 3),
atypical absences (n = 3), infantile spasms (n = 1), and hy-
perkinetic focal seizures (n = 1).
Except for F6, initial development was normal in all patients,
with severe global developmental delay or even regression
coinciding with seizure onset. In F19 and F21, global de-
velopmental delay and seizures were present since birth.
Neurologic examination showed anomalies in most patients
with ataxia being the most frequent ﬁnding.
Seizures were pharmacoresistant in all patients except F18,
undergoing on average 9 AED trials. Only F5 and F21 ach-
ieved seizure freedom with ongoing treatment. Of note, F4
responded with a signiﬁcant seizure reduction to the com-
bined therapy of lamotrigine and valproic acid after several
unsuccessful AED trials. After the administration of bromide,
F14 showed a signiﬁcant reduction in seizure frequency.
EEGs were available for review in 11 of 15 patients. Inter-
ictally, the EEGs in all cases showed multifocal epileptic dis-
charges that were predominantly located in the frontal or
temporal region. In addition, we detected generalized dis-
charges in 10 of 11 patients presenting as generalized spike-
wave or polyspike-wave discharges. In 4 of 11 patients, EEGs
showed frequent bursts of generalized rhythmic activity last-
ing several seconds. Ictal EEG recordings were available in 7
of 11 patients. In 4 patients, typical tonic seizures with gen-
eralized beta activity with increasing amplitude and decreasing
frequency were recorded. EEG curves are available from
Dryad (additional ﬁgures), doi:10.5061/dryad.cf0hj73.
Group 4: Focal epilepsy (2 patients, F22, F23)
F22 had right temporal lobe epilepsy, with a single FS reported at
6 years. Afebrile impaired awareness seizures with automatisms
occurred at the same age. Sometimes she would describe an aura
with a rushing sensation in her head or blurred vision. Occa-
sionally, secondary generalization would occur. Interictal EEGs
showed right temporal epileptiform discharges. Ictal recording
of one seizure depicted a seizure onset over the entire right
hemisphere, with subsequent evolution most prominent over
the right temporal region. Neuropsychological testing and
neurologic examination were unremarkable. Repeated
MRIs showed nonspeciﬁc white matter lesions. An [18F]-
ﬂuorodeoxyglucose–PET at age 28 revealed hypometabolism
in the right temporal lobe. Seizures were pharmacoresistant to
oxcarbazepine, lacosamide, and zonisamide.
In F23, weekly seizures started in teenage years with staring
episodes accompanied by subtle twitching of the right arm. In
addition, GTCS started at 24 years. Seizures were controlled with
lamotrigine. At 45 years, the patient developed stroke-like epi-
sodes featuring left-sided hemicrania, dilatation of the right pupil,
hemihypesthesia, and mild hemiparesis. The episodes lasted be-
tween 30 and 120 minutes and occurred about once a week. An
MRI at age 46 years showed no abnormalities. Previous EEGs
showed left temporal epileptiform discharges. However, the most
recent EEGs were normal. A video-EEG recorded during one of
the stroke-like episodes was without EEG correlate. Of note, in
the patient’s ﬁfth decade of life, several autoimmune diseaseswere
diagnosed: type 1 diabetes mellitus, celiac disease, and hypo-
gammaglobulinemia. Treatment with IV immunoglobulins led to
a decrease in the frequency of the stroke-like episodes.
Molecular genetics
Of the 17 newly identiﬁed variants in STX1B, 8 are missense
(p.Val88Phe, p.Cys144Phe, p.Glu210Lys, p.Leu221Pro,
p.Ala246Pro, p.Ser258Gln, p.Arg261Gln, p.Ile282Thr),
5 frameshift (p.Ser10Alafs*7, p.Gln52Argfs*2, p.Glu128-
Glyfs*2, p.Asn189Alafs*5, p.Thr285Aspfs*75), and 3 stop
gain variants (p.Lys93*, p.Tyr140*, p.Arg245*). One patient
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had a deletion of the entire gene (F20). Syntaxin-1B con-
sists of an N-terminal helical domain, containing the HA,
HB, and HC domains, the SNARE motif, and the C-terminal
transmembrane domain (ﬁgure 1A). When in close proximity
with SNAP-25 and synaptobrevin, syntaxin-1B forms the
SNARE complex that catalyzes membrane fusion in Ca2+-
triggered exocytosis. Syntaxin-1B can adopt 2 conformations:
open and closed. Both conformations are important for exo-
cytosis: the open conformation is necessary for the formation
of the SNARE complex, whereas the closed conformation
initiates the synaptic vesicle fusion reaction.23,24 Figure 1A
shows the new variants combined with those previously
reported in a schematic view of the syntaxin-1B protein. In
comparison to the location of loss-of-function variants, mis-
sense variants were more frequent in the second part of the
gene containing (1) the SNARE motif conveying interaction
with the other 2 components of the SNARE complex and (2)
the transmembrane domain, which is responsible for anchoring
syntaxin-1B into the cell membrane. None of these variants was
reported so far in the gnomAD database, currently the largest
collection of exomes and genomes publicly available.20 In
general, STX1B is intolerant to missense variants (missense z
score >3.63) and haploinsuﬃciency (pLI score of 0.94) in the
Exome Aggregation Consortium browser.20 Evaluation by
diﬀerent in silico prediction tools (SIFT,17 PolyPhen-2,18
MutationTaster19) showed a damaging eﬀect for 6 of 8 variants
in 3 of 3 prediction tools (table 2). We calculated the muta-
tional density of missense variants in the general population
from the Exome Aggregation Consortium using a sliding
window approach and could show that the variants are located
in regions of diﬀerent mutational density (ﬁgure 2B). We also
calculated a paralog conservation score distribution for STX1B
(para_zscore)21 and highlighted the patient variants (ﬁgure
2C). This score gives the degree of conservation among paralog
Figure 1 STX1B gene with variants and pedigrees of newly identified variants
(A) Putative domain structure of syntaxin-1B derived from that for syntaxin-1A,24 as the isoforms share 83.6% of their amino acid sequences (using the
alignment programClustalO39). Shown are the functional domains and depiction of variants. Missense variants are colored in black, other variants are shown
in gray. The boxed variants represent developmental and epileptic encephalopathies. (B) Pedigrees of sporadic patients/families with newly identified
variants. F21 was adopted and there was no information about the biological parents. Abs = absence seizure; AS = atonic seizure; atyp. = atypical; CPS =
complex partial seizure; FE = focal epilepsy; FIAS = focal impaired awareness seizure; GEFS+ = genetic epilepsies with febrile seizures plus; GGE = genetic
generalized epilepsy; GTCS = generalized tonic-clonic seizure; IS = infantile spasms; Myo = generalizedmyoclonic seizure; TMR = transmembrane region; TS =
tonic seizure.
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genes in the human Syntaxin gene family. Disease variants are
enriched in paralog-conserved residues.21 In our paralog anal-
ysis, the SNARE motif turned out to be the most paralog-
conserved and gnomAD variant–depleted region of the protein
with the highest para_zscores (ﬁgure 3, A and B). Furthermore,
in a direct comparison of patient and gnomADmissense variant
distribution across the linear protein sequence, we observed
a signiﬁcant enrichment of patient variants in the SNAREmotif
(p = 0.036). We ascertained missense variants in an unbiased
manner so that SNARE motif enrichment by chance is im-
probable. The amino acid positions of most of the detected
missense variants showed high or intermediate para_zscores.
There was no signiﬁcant diﬀerence between the para_zscores
from missense variant positions in patients compared to those
in gnomAD (ﬁgure 3C). We also detected a few disease-
associated variants in regions with a high mutational density in
gnomAD and low para_zscores (p.Arg261Gln, p.Ile282Thr),
which were located in the transmembrane domain or the part
linking the SNARE motif with the transmembrane domain of
the protein.
Segregation of variants in families and
family histories
The segregation status for all variants in the respective pedi-
grees, together with a classiﬁcation of the phenotypes, is
shown in ﬁgure 1B. Previously published pedigrees can be
found in Schubert et al.12 We validated inheritance in 6 of the
total 23 variants in families with more than one aﬀected (4
new and 2 published). They were mostly cosegregating with
their phenotypes but also included both asymptomatic variant
carriers and phenocopies (F1, 2, 8, 13, 16, 20). In 3 patients,
a positive family history of epilepsy was available, but addi-
tional family members were not available for genetic testing
(F4, 11, 23). The available phenotypes of the other aﬀected
individuals are depicted in ﬁgure 1B.
We showed de novo occurrence for 8 of the remaining 14 var-
iants, which were all detected in sporadic patients (F3, 5, 6, 7, 14,
17, 18, 19), whereas in 6 patients, the respective family members
were not available for segregation analysis (F9, 10, 12, 15, 21, 22).
Discussion
The current study expands the number of reported patients
with STX1B-related epileptic syndromes and describes 17 new
variants. Four diﬀerent phenotypes can be discerned: (1)
a benign epilepsy syndrome with febrile and afebrile seizures
corresponding to GEFS+, (2) a GGE phenotype, (3) a DEE
syndrome with refractory seizures and moderate to severe
developmental deﬁcits, and (4) a focal epilepsy phenotype.
STX1B-related epilepsies thus show a remarkable phenotypic
heterogeneity that is in its extent reminiscent of other epilepsy-
related genes, such as SCN1A,11 SCN2A,25 KCNQ2,26 and
STXBP1.27 In comparison to STXBP1, which is closely related
to STX1B (since the respective proteins interact with each
other in the synaptic transmitter release machinery) and
exhibits in most cases an early onset of epilepsy presenting as
Ohtahara syndrome or West syndrome,28 STX1B-related DEE
shows a later onset of epilepsy after the ﬁrst birthday. Excep-
tions to this rule are F19 (p.A246P) and F21 (p.Q128Gfs*2)
who presented with a seizure onset within the ﬁrst days of life
and are more reminiscent of STXBP1-related syndromes. It is
of interest that STX1B- and STXBP1-related DEEs both feature
ataxia and other movement disorders.28 However, in the vast
majority of STXBP1-related epilepsy syndromes, moderate to
Table 2 Prediction scores and para_zscore of newly identified missense variants
GRCh37/
hg19
position
Alternate
allele
CDS
position
Protein
position
Amino
acids SIFT PolyPhen-2
Mutation
Taster
para_
zscore
16:31004164 G 845 282 I/T Deleterious
(0.01)
Benign (0.104) D (1.0) −2.02
16:31004455 T 782 261 R/Q Deleterious
(0.01)
Probably damaging
(0.981)
D (1.0) −0.38
16:31004464 T 773 258 S/N Tolerated (0.06) Possibly damaging (0.491) D (1.0) −0.71
16:31004501 G 736 246 A/P Deleterious (0) Possibly damaging (0.919) D (1.0) 0.28
16:31004681 G 662 221 L/P Deleterious (0) Probably damaging (1) D (1.0) −0.71
16:31004715 T 628 210 E/K Deleterious (0) Probably damaging
(0.987)
D (1.0) 0.94
16:31008304 A 431 144 C/F Deleterious (0) Probably damaging
(0.998)
D (1.0) 0.28
16:31012267 A 262 88 V/F Deleterious
(0.01)
Probably damaging
(0.913)
D (1.0) 0.94
Abbreviations: PolyPhen-2 = polymorphism phenotyping v2; SIFT = sorting tolerant from intolerant.
Reported missense variants with in silico prediction scores. The table shows the genomic location of the variants in ascending order, the amino acid change,
and the predicted effect of these variants to the protein function by using SIFT, PolyPhen-2, andMutationTaster as well as the paralog conservation score. The
Genome Aggregation Database was used as a source for minor allele frequencies.
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severe developmental delay is present27–29—milder pheno-
types, as in our cohort, are not observed. In comparison to
other common DEE disorders, the median time of seizure
onset diﬀerentiates: neonatal or early infantile for SCN2A and
KCNQ2 (a later onset with these genes is rarer and associated
with diﬀerent functional consequences—gain- vs loss-of-
function mutations25,26,30) and later infantile for SCN1A and
STX1B. Also in other aspects, parallels can be drawn with
SCN1A-related disorders. Thus, in 5 STX1B-related DEE cases,
FS and the presence of myoclonic seizures were reminiscent of
Dravet syndrome.31 However, the presence of tonic seizures in
these patients would be unusual forDravet syndrome. A patient
with generalized tonic-clonic, atonic, and myoclonic seizures
with onset at 1 year and severe developmental delay was
reported before this study with a 1.2 Mb de novo 16p11.2
deletion,13 including the STX1B gene. The phenotype was
classiﬁed as epilepsy with myoclonic-atonic seizures, a syn-
drome that has been associated with SCN1A in several
patients.32 The previously reported patient showed a remark-
able resemblance to F6 and F20, who also harbor a comparable
deletion. Another similarity with SCN1A is that our cohort
features several patients and families with GEFS+ syndrome7
and one patient with mesial temporal lobe epilepsy and FS (for
which commonpolymorphisms in SCN1A have been described
Figure 2Mutational density and paralog conservation scores of STX1B missense variants
(A) Putative domain structure of syntaxin-1B (figure 1A). (B) Variation density in STX1B amino acid positions according to the Genome Aggregation Database
(gnomAD) depicting the reported missense variants. (C) Paralog conservation score (para_zscore) of the STX1B amino acid positions depicting the reported
missense variants (positive values are considered as paralog conserved). Previously reported variants12 are colored in gray, new variants in black. TMR =
transmembrane region.
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as a genetic risk factor33), and at least one GEFS+ multiplex
family with mesial temporal lobe epilepsy has been reported.34
Of interest is our patient with episodes reminiscent of hemi-
plegic migraine; SCN1A mutations are a recognized cause of
familial hemiplegic migraine.35 We acknowledge that the as-
sociation with a migraine-like syndrome in a single patient
could also be coincidental. In contrast, classic GGE syndromes,
such as represented by the 2 patients with JME in our cohort,
are not typically described in patients with SCN1A mutations.
Of note, both patients with JME had an atypical response of
pharmacoresistant seizures. In the DEE group, 7 of 13 (F3, F5,
F6, F14, F17, F18, F19) variants were de novo. This supports
the likelihood of a causative role in the context of the observed
phenotypes. Three missense variants showed a high paralog
conservation (p.C144F, p.G226R, p.A246P), increasing the
probability of a functional role. An exception to this rule was
p.I282T (F14), a variant that was discovered using a gene
panel approach. Possibly, despite the de novo status of this
variant, another as yet unknown genetic alteration in a gene not
captured by the gene panel might be more relevant in this case.
Although variant p.V216E (F4) showed a slightly negative
paralog score, this variant lies in a highly conserved region. The
patient had a positive family history and previous functional
data, i.e., rescue experiments in STX1B knockdown zebra ﬁsh
larvae12 support the pathogenicity of this variant. In F13
(p.N189Afs*5), both aﬀected siblings had a similar phenotype.
This suggests an inheritance from the mother, who has not
been tested, while the father was tested negative. Since the
mother and other maternal family members were reportedly
not aﬀected, germline mosaicism could be possible. However,
other genetic causes cannot be entirely excluded because the
variant was found in a gene panel of 85 epilepsy genes. In F15
(p.S258N), the prediction tools suggest a benign variant. Since
no family members were tested and the paralog score was
rather low, the role of this variant has to be considered carefully.
However, the variant is located at the end of the SNAREmotif,
which supports a causative role. In F16 (p.L221P), the family
history suggests an inherited defect. The variant was identiﬁed
by exome sequencing and no other convincing variants were
found. The unaﬀected mother also carries the variant but other
aﬀected family members were not available for testing. Pre-
diction tools indicate a deleterious variant and the variant is
located in themiddle of the SNAREmotif, although the paralog
score was rather low; a case of incomplete penetrance is
therefore possible or the variant could represent a predisposing
factor for epilepsy. In F20, the gene deletion was inherited from
the father, who had a milder phenotype, suggesting the pres-
ence of other genetic modiﬁers. In F21 (p.Q128Gfs*2), the
parents were not tested and the variant was identiﬁed in a gene
panel of 115 candidate genes, so that other genetic causes
cannot be excluded. In the GEFS+ group, in 3 of 6 cases (F1,
F2, F8), a positive family history with cosegregating genetic
ﬁndings support the causative role of the reported variants. F7
(p.S10Afs7) was conﬁrmed to be de novo. For F9 (p.R245*)
and F10 (p.Y140*), the parents were not tested. Since all
Figure 3 Mutational density and paralog conservation
score of different gene regions
(A) Distribution of mutational density of 4 STX1B gene regions. The SNARE
motif shows the lowest mutational density, the transmembrane region
(TMR) the highest density. (B) Paralog conservation score (para_zscore)
distribution of 4 STX1B gene regions. The SNARE motif shows the highest
paralog conservations, the TMR the lowest conservation. (C) Comparison of
paralog conservation score for all GenomeAggregationDatabase (gnomAD)
variants and patient variants.
e1246 Neurology | Volume 92, Number 11 | March 12, 2019 Neurology.org/N
variants in this group predict a complete loss of function, we
consider them as disease-causing and the mechanism for the
GEFS+ group seems to be clearly a haploinsuﬃciency. In the
GGE group, neither case had parents who were tested. F11
(p.E210K) has a positive family history that is suggestive of an
inherited disease. The causative role of this variant is under-
scored by the in silico ﬁndings that the variant is predicted
deleterious, lies in a region of very low mutational density, and
shows high paralog conservation. p.K93* (F12) leads to
a haploinsuﬃciency, in line with the variants causing GEFS+.
Furthermore, this variant was identiﬁed by whole-genome se-
quencing and no other convincing variants were found. Of in-
terest, in a recent genome-wide association study of common
epilepsies, a signiﬁcant signal in the region of STX1B was
detected in the JME cohort.36 In the FE group, the role of
STX1B should be consideredmore carefully. In F22 (p.R261Q)
and F23 (p.V88F), parents were not tested. For p.R261Q, the
established prediction tools point toward a deleterious variant,
while the position shows medium mutational density and low
paralog conservation. However, whole-genome sequencing
showed no other likely pathogenic variants. For p.V88F, the
used prediction tools show a more coherent picture of a dele-
terious variant, the paralog score was high, and whole-exome
sequencing found no other convincing variants.
Regarding genotype-phenotype correlation, it is notable that
missense variants in the functionally relevant SNARE motif
were identiﬁed in 6 of 7 patients or families (86%) associated
with DEE. The seventh patient (p.E210K) had refractory
JME. In contrast, all but one of the GEFS+ patients or families
had truncating variants (5 of 6, 83%) predicting nonsense-
mediated decay and complete loss of function of one allele
indicating haploinsuﬃciency as the disease mechanism.
A possible explanation could be that missense variants in crucial
protein regions, such as the SNAREmotif, may lead to a deﬁcient
gene product that interferes with protein-protein interactions and
normal presynaptic vesicle fusion (dominant-negative eﬀect),
whereas missense variants in the ﬁrst part of the gene may aﬀect
assembly of syntaxin-1B proteins and therefore have similar
consequences as a truncation with nonsense-mediated decay.
The loss-of-function mechanisms could also be compensated—
at least in part—by syntaxin-1A and, thus, be less damaging.37
We demonstrate that STX1B variants are linked to 4 diﬀerent
epilepsy phenotypes. De novo dominant mutagenesis is the eti-
ology of most DEEs, whereas the more common epilepsies are
likely complex genetic disorders. This work suggests a role for
ultrarare STX1B variants in the pathogenesis of a broad range of
both common and rare epilepsies. There are plausible explan-
ations for genotype-phenotype correlations, such that hap-
loinsuﬃciency causes rather benign phenotypes, whereas
missense variants in functionally critical regions cause more se-
vere phenotypes. Other, unknown factors, which may include
genetic modiﬁer, individual genetic background, and epigenetic
eﬀects, could also have an important role and explain phenotypic
heterogeneity, reduced penetrance, and variable phenotypes
among carriers of truncating mutations. Functional studies on
a protein and cellular neuronal level will shed more light on the
relevance and degree of severity of the described variants and
contribute to a better understanding of the dysfunction of
syntaxin-1B and synaptic transmission in epilepsy and strengthen
our current interpretation of genotype-phenotype correlations.
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